The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. [electronic resource]
Producer: 20120504Description: 29-37 p. digitalISSN:- 1432-1041
- Adult
- Antipsychotic Agents -- adverse effects
- Aripiprazole
- Biotransformation
- Cytochrome P-450 CYP2D6 -- genetics
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP3A
- Cytochrome P-450 CYP3A Inhibitors
- Drug Interactions
- Enzyme Inhibitors -- adverse effects
- Fluvoxamine -- adverse effects
- Genetic Association Studies
- Half-Life
- Humans
- Japan
- Male
- Metabolic Clearance Rate -- drug effects
- Paroxetine -- adverse effects
- Piperazines -- adverse effects
- Polymorphism, Genetic
- Quinolones -- adverse effects
- Serotonin 5-HT2 Receptor Antagonists -- adverse effects
- Selective Serotonin Reuptake Inhibitors -- adverse effects
- Young Adult
No physical items for this record
Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.